The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
I need to know what I'm backing, not blindly put cash in, my average is already £5 and I don't intend on that going any higher unless I know for sure the SP really is undervalued. We could have a hundred different product launches available in 200 countries, but if sales are 6 figures total then we have a problem.
I'm not putting a penny more in until GM gives us some sales figures, I think pi's have done enough legwork and being kept in the dark. Let shorters do their thing, if GM doesn't care, then neither do I.
C'mon Craig, we're all on the same team. There's a lot of money to be made in gluing two bits of plastic together - its an incredibly complex and profitable process. Its why Apple manufacture everything themselves in house rather than outsource it to some 15 year olds in China.
Oh wait.
Iso certification (assuming they've used BSI, like other major pharmas have, Inc Mologic) directory here. Avacta not showing yet. As I mentioned before it could be their audit was at end of march, and Al might have assumed certification was immediate (BSI recommend that you're awarded certification, they don't award it there and then), or it might be have some minor none conformities that need resolving on their QMS before certification awarded, either way it could take up to 2 weeks after successful second audit to having the certificate in your hand.
https://www.bsigroup.com/en-GB/our-services/certification/certificate-and-client-directory/
I'm expecting no further RNS this tax year (though still hopeful), will give the chance to get some shares on the cheap from the panicked.
Energy - that would be extremely risky by govt then to put machines in place to the likes of odx if it rules out certain tests. I know feck all about manufacturing but wouldn't it be more likely the govt have specified exact dimensions of a test, and avacta or whoever just need to design and/or supply the innards?
Good point about the reagent, I have no idea on surescreens capacity.
The ties between odx and surescreen is they're both members of the rapid antigen test consortium
I have no doubt we'll have a fantastic test, testing will be needed for years so not worried at all, and should our mologic double act arrive before winter I imagine that will be in huge demand worldwide
Arent't the govt just waiting to see our results before committing fully to a test? Even if surescreen met test requirements it would make sense to see what else comes on to market before tender deadline rather than announce early - thats not how tenders work. Govt couldnt give surescreen a huge order as at the time they wouldnt have the resources to meet it - 20m was about the limit and this required a large increase in their workforce, new premises etc, ODX, GAD etc didnt have capacity either at the time. Al is trying to get our test through validation before tender ends, hence other projects put on hold/had resources moved.
Not deramping as I'm balls deep here, but Surescreen are part of the RATC, are cheap (£6m for 20m units), and while not as good as roche or abbotts lft according to the BMJ, its better than innova, meets min requirements and as said have previous orders from govt in.
We can probably win based on test quality and ease / speed of altering to meet future variants, surescreen could win on price, being known to govt already, and Tory govt can't be accused of making us shareholders rich with tax payers money. At the end of the day, not getting the UK contract wouldn't be the end of the world, more money could be made with fewer units elsewhere. Getting the damn test to market is the most important thing and proving affimers work!
Is surescreens test even as good as mologics?
Comparison here, granted it's CT < 30 (I don't have comparible figures for Mologic) and using brain stabber method rather than AN, but unless I'm interpreting it wrong, sensitivity is pretty poor in comparison to others tested from likes of Siemens, abbot and Roche?
https://www.medrxiv.org/content/10.1101/2021.02.11.21251553v1.full.pdf&ved=2ahUKEwjz3O-c_c7vAhUHesAKHWsZCCQQFjADegQIFRAC&usg=AOvVaw1MaooSJe3yy0Jf2a4JGM7I
Exactly wolverine - you dont go and and increase your workforce by over 50% on the hope of getting a contract - you do that because you know you'll need them on board to meet demand as the existing workforce which has brought in £250m+ in sales no longer has capacity to increase that at the same rate. Terms of the contract may demand X number of tests performed at x location, and nova have been given time (or more likely a heads up) to put capacity in place.
GM will no doubt be on good first name basis with govt contacts, and my experience of those high up in the NHS, CCGs, Royal colleges, ICSs is they're all still driven by relationships - once you've built a successful partnership, things are going well, they dont want to change, repeat tendering is easier once you're on board and on familiar terms. Was easier before lockdown mind when you could take the key gov decision makers out down the pub, or end up in middle of Liverpool at 4.00 being kicked out a club. The old cliche about business being done on the golf course is still true, although public sector it still happens down the pub. If GM is an alcy we're in with a shout.
"Sorry didn’t realise it had been discussed ..just seems another alternative to lateral flow and PCR and another option for anyone wanting any potential exposure TTG is a manufacturing partner"
Its an alternative to LFT and PCR in the same way using your fingers to cut the grass compared to getting the lawnmower out the shed and plugging it in. Quicker I suppose if your garden consists of some strands poking between the slabs, but any more than a ft sq needs a proper tool. Apply that analogy however way you see fit.
Don't be daft, Pedro, that would help shareholders make an informed decision. What we need is more product launches and panels with zero mentions of any sales. Does the same guy here write the RNSs for ODX too?
All we need is a simple RNS trading update. Doesn't even need to mention DHSC or govt orders, just a simple, "we've fulfilled £Xm orders in our last trading quarter, and a further £Xm orders are waiting to be fulfilled." I dont need to know what was sold or to whom, at this stage I really don't care, I just need to to is £20m a month coming in, or £0.2m
Strange, as the r&d relief in UK for SME (500 employees or less, up to 100m euro turnover) is extremely generous at 230%. Id be abusing that to the hilt if it was my company, would never pay corporation tax again!
MrA - Lots of companies have developed/are developing tests, vast majority are either too expensive, not appropriate, too inaccurate, cannot be upscaled and dont have the UK wide collaborations in place. And more importantly, none have affimers. Maybe they'd like to licence some?
Similar issue car manufacturers are having with electric cars - none have access to the tesla charging network (affimers), all are trying to go it alone using sh*tty infrastructure. Anyone can shove a battery and motor in a car and call it done. Tesla might not be the cheapest, but they're doing ok and their name is synonymous with electric cars, just like ours will be 6 months from now with Lateral flow tests.